Combined Analysis of Phase III Trials Evaluating [(99m)Tc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma

BACKGROUND: [(99m)Tc]Tilmanocept is a CD206 receptor-targeted radiopharmaceutical designed for sentinel lymph node (SLN) identification. Two nearly identical nonrandomized phase III trials compared [(99m)Tc]tilmanocept to vital blue dye. METHODS: Patients received [(99m)Tc]tilmanocept and blue dye....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sondak, Vernon K., King, Dennis W., Zager, Jonathan S., Schneebaum, Schlomo, Kim, Julian, Leong, Stanley P. L., Faries, Mark B., Averbook, Bruce J., Martinez, Steve R., Puleo, Christopher A., Messina, Jane L., Christman, Lori, Wallace, Anne M.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer-Verlag 2012
Assuntos:
Melanomas
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3560941/
https://ncbi.nlm.nih.gov/pubmed/23054107
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-012-2612-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados